The Claim
One year after treatment cessation, individuals who previously received supervised exercise (with or without liraglutide) engaged in higher levels of moderate-to-vigorous physical activity compared to individuals who received liraglutide alone or placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
One year after stopping treatment, people who had done supervised exercise during their treatment were more active in moderate-to-vigorous physical activity than those who only took liraglutide or a placebo.
See the scientific wording
One year after treatment cessation, participants who previously received supervised exercise (with or without liraglutide) engaged in significantly more moderate-to-vigorous physical activity than those who received liraglutide alone or placebo, suggesting exercise training may promote lasting behavioral change.
Repeated physical activity during supervised training strengthens brain circuits that make movement automatic, so people keep being active even after the program ends. This keeps their metabolism high and prevents weight gain, while stopping a weight-loss drug causes hunger to surge and energy use to drop, leading to rapid weight regain.
What the research says
1 studyPeople who did supervised exercise during the study stayed lighter a year after stopping, even though they weren’t being watched anymore — this suggests they kept being active on their own. Those who only took the weight-loss drug gained most of the weight back.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.